SLC5A2 and cardiovascular disorder: By contrast, data from the Department of Defense database [13] showed that individuals with type 2 diabetes and established cardiovascular disease treated with SGLT2 inhibitors (mostly canagliflozin) compared with other glucose-lowering therapies (n = 12,629 matched pairs) had an increased risk of amputation (HR 1.99 [95% CI 1.12, 3.51]) directly comparable in magnitude with that observed in the CANVAS Program.